Oncocyte Q1 revenue $2.14M, gross margin 62%; transplant trial gets IRB approval

Insight Molecular Diagnostics Inc.

2025-Q1 EPS reported -$0.26 revenue$2,138,000

Q1 2025 pharma services revenue $2.14M with 62% gross margin, up from 40% in Q4 2024.
Net loss $6.7M ($0.26 per share); non-GAAP loss from operations $5.0M.
Clinical trial design completed, central IRB approved; three top-10 US transplant centers expected to participate.
Ten leading transplant centers now using GraftAssure RUO kits; company plans to rename in Q2.
Cash balance $32.7M at quarter-end, including $28.7M net from February offering; Q1 operating cash use $5.9M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.